Terumo (TRUMY) Stock Price, News & Analysis

Company Overview

Terumo Corporation is a Japan-based medical technology company that develops, manufactures and sells products used in hospitals, clinics and other healthcare settings. Founded in 1921 by a group of Japanese medical doctors, the company initially produced clinical thermometers and has since expanded into a global provider of medical devices and related services.

Terumo’s principal businesses include cardiac and vascular products, blood and cell technologies, and general hospital solutions. Its portfolio includes interventional devices and systems used in cardiovascular procedures, blood collection and processing equipment, transfusion products, infusion and injection devices, and other products designed to support patient care and clinical workflows. The company also provides technologies for diabetes management and other specialized medical applications.

Terumo serves healthcare providers and patients internationally through operations and distribution networks spanning Japan, the Americas, Europe, Asia and other markets. Its products are used across a range of medical specialties, including cardiovascular care, blood management, interventional procedures, infusion therapy and hospital operations.

Key Stats

• Today's Range: $14.51 to $14.88
• 50-Day Range: $13.25 to $16.67
• 52-Week Range: $12.08 to $17.81
• Volume: 117,507 shs
• Average Volume: 68,365 shs
• Market Capitalization: $21.80 billion
• P/E Ratio: 20.82
• Dividend Yield: 0.74%
• Price Target: N/A
• Consensus Rating: Buy

Terumo Stock Analysis - MarketRank™

Terumo scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Buy

Consensus Rating

Terumo has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Terumo has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -6.98%

Earnings Growth

Earnings for Terumo are expected to decrease by -6.98% in the coming year, from $0.86 to $0.80 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Terumo is 20.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.52.

Price to Earnings Ratio vs. Sector

The P/E ratio of Terumo is 20.82, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.64.

Price to Book Value per Share Ratio

Terumo has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Terumo has been sold short.

Short Interest Ratio / Days to Cover

Terumo has a short interest ratio ("days to cover") of 0.23, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Terumo has recently decreased by 71.20%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Terumo has a dividend yield of 0.77%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Terumo does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Terumo is 15.49%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Terumo will have a dividend payout ratio of 13.75% next year. This indicates that Terumo will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Terumo has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Terumo this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Terumo insiders have not sold or bought any company stock.

Percentage Held by Institutions

Terumo has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 10/01/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:TRUMY
• Previous Symbol: NASDAQ:TRUMY
• CIK: 1446672
• Web: www.terumo.com
• Phone: (133) 374-8111
• Fax: 813-3374-8399
• Employees: 30,000
• Year Founded: 1964

Profitability

• EPS (Trailing Twelve Months): $0.71
• Trailing P/E Ratio: 20.82
• Forward P/E Ratio: 17.19
• P/E Growth: N/A
• Net Income: $897.03 million
• Net Margins: 13.83%
• Pretax Margin: 15.75%
• Return on Equity: 10.44%
• Return on Assets: 7.34%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 2.19
• Quick Ratio: 1.37

Sales & Book Value

• Annual Sales: $7.52 billion
• Price / Sales: 2.90
• Cash Flow: $1.07 per share
• Price / Cash Flow: 13.85
• Book Value: $7.09 per share
• Price / Book: 2.08

Miscellaneous

• Outstanding Shares: 1,475,070,000
• Free Float: N/A
• Market Cap: $21.80 billion
• Optionable: Not Optionable
• Beta: 0.77